Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Filing with SEC Marks Milestone Paving Way For Company to Uplist to National Exchange
Highlights Achievements for 2013
NEW YORK-- Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, filed its 2013 Annual Report on Form 10-K with the Securities and Exchange Commission ("SEC"). This Annual Report on Form 10-K includes audited financial statements for the year ended December 31, 2013. With the filing of the Company’s Form 10-K with the SEC, the Company has completed the stock exchange “seasoning” requirements to uplist to a national exchange. For companies that have become SEC reporting companies through a reverse merger, seasoning requirements include, among other things, the timely filing of all required reports since the reverse merger, including the filing of at least one annual report on Form 10-K, the company being traded for at least one year in the U.S. over-the-counter market, and maintenance of a minimum stock price.
“Filing this annual report on Form 10-K is a major milestone for the Company,” said Kaushik J. Dave, Ph.D., President and CEO of Actinium Pharmaceuticals. “We believe that we are now poised to establish a relationship with a national stock exchange and move forward in developing our lead drug, Iomab™-B, which is in clinical trials to prepare patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.”
Other corporate and clinical milestones achieved during 2013 include:
- Actinium completed its first year as a public company, successfully completing a share exchange agreement at the end of December 2012 and trading as a public company.
- Raised approximately $10.1 million in capital through the exercise of warrants and financings which included the offering concluded January 6, 2014.
- Strengthened its management team and Board of Directors with the appointment of Kaushik J. Dave, Ph.D., MBA as CEO. With nearly 25 years of broad biotech and pharmaceutical experience at both large and emerging growth biopharmaceutical companies, Dr. Dave brought several drugs to the market. He brought new leadership to the company.
- Appointed Corey Sohmer as Vice President of Finance and Business Development, whose broad financial background in the biotech industry added depth to the management team.
- Appointed industry veteran Richard I. Steinhart to its Board of Directors and as Chairman of the Audit Committee and member of the Compensation Committee.
- Initiated an investor relations program, presented at several industry conferences and achieved its first coverage by a brokerage firm analyst.
- Held a successful Iomab-B End of Phase 2 (EOP-2) meeting and established an agreement with the FDA on the path to a Biologics License Application (BLA) submission which includes only a single pivotal Phase 3 clinical study. The FDA agreed that the study design of the pivotal trial may be adequate to support the license indication as a single study, providing that results are sufficiently robust that it would be unethical to repeat the study.
- Continued development of Actimab™-A, and is currently in development in a Phase 1/2 trial for newly diagnosed Acute Myeloid Leukemia patients.
Looking ahead over the next 12-18 months, the Company expects to achieve the following milestones that it believes will drive value:
- Commence Phase 3 Company sponsored multicenter pivotal Iomab-B clinical study.
- Complete the Phase 1 trial and commence the Phase 2 trial for Actimab-A.
- Uplist to a national exchange.
- Continue investor outreach and achieve additional analyst following.
Dr. Dave said, “This has been a monumental year for Actinium Pharmaceuticals. We look forward to making progress on our clinical programs and bringing to market our targeted immunotherapeutics to treat patients with advanced cancers.”
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Corey Sohmer, 646-459-4201
Source: Actinium Pharmaceuticals, Inc.
Released March 5, 2014